skip to main content

SLE — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateSLE & Antiphospholipid SyndromeSLESCE Rheumatology

A 52-year-old woman with SLE on long-term Hydroxychloroquine and Azathioprine presents with a flare of arthritis and rash. Her anti-dsDNA has risen and complement has fallen. According to EULAR 2023, which biologic should be considered to facilitate glucocorticoid dose reduction without waiting for conventional immunosuppressive failure?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Belimumab or Anifrolumab

EULAR 2023 recommends prompt initiation of immunosuppressive drugs and/or biological agents (Belimumab, Anifrolumab) to control disease activity and facilitate glucocorticoid tapering. Importantly, prior use of a conventional immunosuppressive is NOT mandatory before starting a biologic in SLE. This represents a shift toward earlier biologic use. Rituximab is reserved for organ-threatening and refractory disease. Tocilizumab, Abatacept, and Infliximab are not licensed or recommended for SLE.

Reference: EULAR 2023 - Recommendations for management of SLE